Table 1.
Demographics and clinical features of the study populationa
| Subject-level characteristic | Value for all subjects (n = 90) |
|---|---|
| No. (%) of subjects of gender | |
| Female | 51 (56) |
| Male | 39 (44) |
| No. (%) of subjects of race | |
| Caucasian | 51 (57) |
| Non-Caucasian | 39 (43) |
| Median age (yr) (range) | 31 (18–63) |
| No. (%) of subjects with HSV status of: | |
| HSV-1 seropositive | 32 (35) |
| HSV-2 seropositive | 06 (07) |
| HSV-1 and HSV-2 seropositive | 05 (06) |
| HSV seronegative | 47 (52) |
| No. (%) of subjects with herpes disease status of: | |
| Seropositive symptomatic | 10 (11) |
| Seropositive asymptomatic | 33 (37) |
a
Sera from a total of 90 individuals attending the UCI Medical Center were used to probe the chips displaying the HSV-1 and HSV-2 protein microarrays. These 90 individuals were comprised of 32 HSV-1-, 6 HSV-2-, and 5 HSV-1/HSV-2-seropositive and 47 HSV-1- and HSV-2-seronegative individuals. Sera from all 90 individuals were serotyped by a using commercial gG1 and gG2 ELISA (FocuSelect 1 and 2 IgG). The seronegative individuals were used as negative controls and were used to establish baseline responses for each antigen.